Find a Trial

(EXPANSION) A Phase I/IIa, Open-label, Multi-center Study to Assess the…

Condition:

TO Study:

Clinic:

Protocol:

NCT04140526

Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single…

Condition: Multiple Solid Tumors

TO Study: MULTI 67

Clinic: Cleveland, Downtown, MedPark 2, Memorial

Protocol: ONC-392-001

NCT06171685

MMRC HORIZON ONE: A PHASE II RANDOMIZED ADAPTIVE PLATFORM TRIAL…

Condition: Multiple Myeloma

TO Study: MM24011

Clinic: Midtown, Midtown Center for Blood Cancer, Tennessee Oncology Center for Blood Cancer

Protocol: MMRC-099

NCT05827016

Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide…

Condition: Multiple Myeloma

TO Study: MM 163

Clinic: Centennial Medical Center, Dickson, Franklin, Gallatin, Hendersonville, Lebanon, Midtown, Midtown Center for Blood Cancer Murfreesboro, St. Thomas West, Shelbyville, Skyline, Smyrna, Southern Hills, Tennessee Oncology Center for Blood Cancer

Protocol: IM048022

NCT05722418

Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic…

Condition: Multiple Myeloma

TO Study: MM 161

Clinic: Midtown Center for Blood Cancer, Tennessee Oncology Center for Blood Cancer

Protocol: CB-011

NCT05651932

A Phase 1 Study of KTX-1001, an Oral, First-In-Class, Selective,…

Condition: Multiple Myeloma

TO Study: MM 159

Clinic: Tennessee Oncology Center for Blood Cancer, Midtown Center for Blood Cancer

Protocol: K36 MMSET-001

NCT04975997

A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide,…

Condition: Multiple Myeloma

TO Study: MM 136

Clinic: Lebanon?, Murfreesboro, Shelbyville?, Summit, Midtown Center for Blood Cancer?, Midtown?, Centennial Medical Center?, Gallatin, Tennessee Oncology Center for Blood Cancer

Protocol: CC-220- MM-002

NCT03399799

A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64407564,…

Condition: Multiple Myeloma

TO Study: MM 96

Clinic: Midtown Center for Blood Cancer, Tennessee Oncology Center for Blood Cancer

Protocol: 64407564MMY1001

NCT05006716

A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the…

Condition: Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia

TO Study: LYM23005

Clinic: Midtown, Midtown Center for Blood Cancer, Tennessee Oncology Center for Blood Cancer

Protocol: BGB-16673-101

NCT05950334

A Phase 1 Study of FT522 in Combination With Rituximab…

Condition: Large B-Cell Lymphoma

TO Study: LYM23002

Clinic: Midtown Center for Blood Cancer, Tennessee Oncology Center for Blood Cancer

Protocol: FT522-101

NCT05798897

A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen Specific T…

Condition: Chronic Lymphocytic Leukemia, Follicular Lymphoma, Hodgkin Lymphoma, Large B-Cell Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma

TO Study: LYM 211

Clinic: Midtown Center for Blood Cancer, Tennessee Oncology Center for Blood Cancer

Protocol: MRKR-22-601-01

NCT04561206

Brentuximab Vedotin and Nivolumab for the Treatment of Patients With…

Condition: Classical Hodgkin Lymphoma

TO Study: LYM 189

Clinic: Centennial Medical Center, Dickson, Franklin, Gallatin, Hendersonville, Lebanon, Midtown, Midtown Center for Blood Cancer Murfreesboro, St. Thomas West, Shelbyville, Skyline, Smyrna, Southern Hills, Tennessee Oncology Center for Blood Cancer

Protocol: 20147

NCT05605899

An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare…

Condition: Large B-Cell Lymphoma

TO Study: LYM 206

Clinic: Midtown Center for Blood Cancer, Tennessee Oncology Center for Blood Cancer

Protocol: KT-US-484-0136

NCT05371093

A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy…

Condition: Follicular Lymphoma

TO Study: LYM 202

Clinic: Midtown Center for Blood Cancer, Tennessee Oncology Center for Blood Cancer

Protocol: KT-US-473-0133

NCT04830137

A Phase 1, Dose Escalation, Safety and Tolerability Study of…

Condition: Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Primary Central Nervous System Lymphoma, Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia

TO Study: LYM 184

Clinic: Midtown Center for Blood Cancer, Tennessee Oncology Center for Blood Cancer

Protocol: NX-2127

NCT04224493

Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive…

Condition: Follicular Lymphoma

TO Study: LYM 170

Clinic: Centennial Medical Center, Dickson, Franklin, Gallatin, Hendersonville, Lebanon, Midtown, Midtown Center for Blood Cancer Murfreesboro, St. Thomas West, Shelbyville, Skyline, Smyrna, Southern Hills, Tennessee Oncology Center for Blood Cancer

Protocol: EZH-302

NCT05565378

A Phase 2, Randomized, Open-label, Platform Study Utilizing a Master…

Condition: Non-small Cell Lung Cancer

TO Study: LUN23023

Clinic: Cleveland, Downtown, MedPark 2, Memorial

Protocol: 213824

NCT06497556

A Study Evaluating the Efficacy and Safety of Divarasib Versus…

Condition: Non-small Cell Lung Cancer

TO Study: LUN23013

Clinic: Centennial Medical Center, Dickson, Franklin, Gallatin, Hendersonville, Lebanon, Midtown, Murfreesboro, St. Thomas West, Shelbyville, Skyline, Smyrna, Southern Hills

Protocol: BO45217

NCT04756726

A Phase I/II Open-Label Multi-Center Study to Characterize the Safety…

Condition: Multiple Myeloma

TO Study: HR 68

Clinic: Tennessee Oncology Center for Blood Cancer, Midtown Center for Blood Cancer

Protocol: CFT7455-1101

NCT05645692

A Phase II, Randomized, Multicenter, Open-Label, Controlled Study of Tobemstomig…

Condition: Urothelial Cancer

TO Study: GU 220

Clinic: Cleveland, Downtown, MedPark 2, Memorial

Protocol: BO44157

NCT04468061

Saci-IO TNBC: Randomized Phase II Study of Sacituzumab Govitecan With…

Condition: Breast Cancer: Triple Negative

TO Study: BRE 360

Clinic: Cleveland, Downtown, MedPark 2, Memorial

Protocol: 20-166

NCT06073821

A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus…

Condition: Chronic Lymphocytic Leukemia

TO Study: CLL24003

Clinic: Cleveland, Downtown, MedPark 2, Memorial, Dalton, Ringgold, Centennial Medical Center, Dickson, Franklin, Gallatin, Hendersonville, Lebanon, Midtown, Midtown Center for Blood Cancer Murfreesboro, St. Thomas West, Shelbyville, Skyline, Smyrna, Southern Hills, Tennessee Oncology Center for Blood Cancer

Protocol: BGB-11417-301

NCT04116437

A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in…

Condition: Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia

TO Study: CLL 50

Clinic: Tennessee Oncology Center for Blood Cancer, Lebanon, Murfreesboro, Shelbyville, Summit, Midtown Center for Blood Cancer, St. Thomas West, Gallatin

Protocol: BGB-3111-215

NCT06103864

A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd)…

Condition: Breast Cancer: Triple Negative

TO Study: BRE23006

Clinic: Cleveland, Downtown, MedPark 2, Memorial, Centennial Medical Center, Dickson, Franklin, Gallatin, Hendersonville, Lebanon, Midtown, Murfreesboro, West, Shelbyville, Skyline, Smyrna, Southern Hills, Summit

Protocol: D7630C00001

NCT06112379

Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan(Dato-DXd) Plus…

Condition: Breast Cancer: Triple Negative

TO Study: BRE23005

Clinic: Cleveland, Downtown, MedPark 2, Memorial, Centennial Medical Center, Dickson, Franklin, Gallatin, Hendersonville, Lebanon, Midtown, Murfreesboro, West, Shelbyville, Skyline, Smyrna, Southern Hills, Summit

Protocol: D926QC0001

NCT05629585

A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (DatoDXd)…

Condition: Breast Cancer: Triple Negative

TO Study: BRE 409

Clinic: Cleveland, Downtown, MedPark 2, Memorial

Protocol: D926XC00001

NCT05774951

A Phase III, Open-Label, Randomised Study to Assess the Efficacy…

Condition: Breast Cancer: HR+/HER2-

TO Study: BRE 405

Clinic: Cleveland, Downtown, MedPark 2, Memorial

Protocol: D8531C00002